NEW YORK (GenomeWeb) – Talis Biomedical said today that CARB-X has awarded it $4.4 million to further its point-of-care technology for pathogen identification and antibiotic-susceptibility testing.
The award will go toward development of Talis Bio's rapid CLIA-waived molecular diagnostic test for detecting chlamydia and gonorrhea directly from a patient's sample in no more than 20 minutes, as well as a rapid phenotypic antibiotic susceptibility test for gonorrhea.
Talis Bio's technology, called SlipChip, is based on isothermal amplification, and combined with data science tools allows users to load samples, walk away, and view test results remotely. By measuring small differences in molecular responses between susceptible and resistant bacteria, SlipChip can determine antibiotic susceptibility, the company said, adding SlipChip is being developed so that physician offices and clinics can run reference lab-quality diagnostic tests.
Talis Bio also intends to build out its testing menu beyond chlamydia and gonorrhea, Talis Bio CEO Brian Coe said in a statement.
The Menlo Park, California-based firm said that it is also eligible for an additional $4.2 million milestone-based award from CARB-X, a public-private partnership to accelerate development of early-stage antibiotics and diagnostics for drug-resistant bacterial infections.